CytoDyn Inc. (OTCQB: CYDY) reported on Thursday night that it started a phase 3 clinical trial to consider the company’s investigational drug leronlimab to treat COVID-19. The biotech company announced that it has started treating its first patient in Brazil with severe symptoms from the pandemic disease.
“We are very encouraged enrollment for this first trial is underway and look forward to reaching our interim analysis target as soon as possible,” said CytoDyn CEO Nader Pourhassan, Ph.D.
Leronlimab is a humanized monoclonal antibody targeted against a specific receptor in a human’s T-cell to trigger an immune system response. The US Food and Drug Administration previously granted the firm a fast track designation to use the candidate drug as a possible treatment for HIV-related diseases and metastatic cancer. After completing two clinical trials for the drug to treat COVID-19 patients, the firm initiated a phase 2 investigative trial for the drug’s use in treating patients with enduring symptoms, also known as COVID-19 long-haulers.
Following the treatment of the first COVID-19 patient in Brazil, a 28-day interim analysis will be conducted which will determine the further enrollment of 245 more patients to the trial. The results are intended to give the country’s regulatory body, Agência Nacional de Vigilância Sanitária, the necessary data to support the use of leronlimab on treating COVID-19.
CytoDyn last traded at $1.275 on the OTCQB.
Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
